0001437749-22-015778.txt : 20220623
0001437749-22-015778.hdr.sgml : 20220623
20220623195451
ACCESSION NUMBER: 0001437749-22-015778
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220621
FILED AS OF DATE: 20220623
DATE AS OF CHANGE: 20220623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Powchik Peter
CENTRAL INDEX KEY: 0001377247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41058
FILM NUMBER: 221036705
MAIL ADDRESS:
STREET 1: REGENERON PHARMACEUTICALS, INC.
STREET 2: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxxinity, Inc.
CENTRAL INDEX KEY: 0001851657
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 862083865
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1717 MAIN STREET
STREET 2: SUITE 3388
CITY: DALLAS
STATE: TX
ZIP: 75201
BUSINESS PHONE: (254) 244-5739
MAIL ADDRESS:
STREET 1: 1717 MAIN STREET
STREET 2: SUITE 3388
CITY: DALLAS
STATE: TX
ZIP: 75201
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-06-21
0001851657
Vaxxinity, Inc.
VAXX
0001377247
Powchik Peter
1717 MAIN STREET
SUITE 3388
DALLAS
TX
75201
1
Class A common stock
225858
D
Stock option (right to buy)
2.09
2022-06-21
4
A
0
129187
0
A
Class A common stock
129187
129187
D
Stock option (right to buy)
4.3000
2032-03-31
Class A common stock
94186
94186
D
These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date.
These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
These options are subject to a three-year time-vesting schedule, with 31,395 shares vesting on the first and second anniversaries of the grant date and the remainder vesting on the third anniversary of the grant date.
The expiration date was incorrectly reported as "03/31/2022" in the Form 4 filed on April 4, 2022.
/s/ Rene Paula Molina, attorney-in-fact for Peter Powchik
2022-06-23